RDY Dr. Reddy's Laboratories Limited: Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Simbol lan logo merek drreddys.com (RDY)

The dynamics of consensus EPS forecasts for the coming year show that Dr. Reddy's Laboratories (RDY) has reached the level of 34.30. Growth is supported by low costs and the development of complex injectable products. This positive trajectory is driven by the launch of biosimilars into the US market and oncology partnerships. Stable potential is ensured by attracting leading chemists through large-scale investments in modern research centers.

RDY: Prakiraan wutah bathi resik saben siji saham kanggo taun ngarep Dr. Reddy's Laboratories Limited 04.07.2022 - 17.11.2026

Dr. Reddy's Lab - rincian analitis lan metrik utama (RDY)

- rega saham lan konsensus proyeksi valuasi:
- data kapitalisasi saham perusahaan:
Analisis wiwitan perusahaan:Dr. Reddy's Laboratories
Barang utama Dr. Reddy's Laboratories Limited

For Dr. Reddy's Laboratories (RDY), this indicator serves as a tool for assessing future profitability amid a high dependence on external contractors. The forward earnings per share trend is based on the analyst consensus for annual EPS changes, reflecting the expected percentage growth in net income. The increase in this metric confirms the efficiency of generic drug development outsourcing and logistics optimization. The stability of this line testifies to the fundamental resilience of the company's business model.